Endocyte, Inc.

Endocyte, Inc. is a biotechnology company focused on innovative cancer therapies and companion diagnostics, leveraging targeted therapies to enhance patient outcomes in oncology. Founded in 1995 and headquartered in West Lafayette, Indiana, Endocyte, Inc. specializes in developing targeted therapeutics for cancer treatment.

The company completed its initial public offering in February 2011, raising approximately USD 75 million. Endocyte has engaged in 9 deals, with its latest deal occurring on February 9, 2011. The firm has not been reported as having any subsidiaries or parent companies. Endocyte, Inc.

develops novel therapeutic candidates that target cancer cells specifically, offering advanced solutions to address unmet medical needs in oncology. The company's key focus is on leveraging its expertise in targeted therapies to create effective treatment options for patients with various types of cancer, ensuring that healthcare providers have access to tailored therapies designed to improve patient outcomes across diverse markets globally. In the most recent financial year of 2017, Endocyte, Inc. reported revenue of USD 70,000, with an EBITDA of USD -55,183,375.

Endocyte, Inc. aims to utilize the proceeds from its IPO to support the development of new therapeutic products and explore opportunities for expansion into additional geographic markets. The company is focused on advancing its pipeline of targeted cancer therapies and enhancing its market presence in North America and Europe by leveraging innovative research and development initiatives. The funding achieved from the IPO will be critical in facilitating these growth strategies.